Coccidioidomycosis Market

Market Overview:

The 7 major coccidioidomycosis markets reached a value of US$ 132.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 209.5 Million by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.

The coccidioidomycosis market has been comprehensively analyzed in IMARC's new report titled "Coccidioidomycosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Coccidioidomycosis, also known as valley fever, refers to a fungal infection that arises due to the inhalation of spores from the fungi Coccidioides posadasii or Coccidioides immitis. The indications of this condition can vary widely, ranging from mild flu-like symptoms to serious and potentially life-threatening complications. The ailment usually manifests as fever, cough, fatigue, headache, and muscle aches. In some cases, the disorder can progress to a more severe form, leading to pneumonia, skin rashes, joint pain, and, rarely, dissemination to several other organs, like the brain and bones. The diagnosis of coccidioidomycosis typically involves a combination of clinical evaluation, imaging studies, physical examination, and laboratory tests. The healthcare provider may also conduct blood workups to detect antibodies against the fungi or use imaging techniques, such as CT scans or chest X-rays, to identify characteristic lung lesions. In severe cases or when dissemination is suspected, a biopsy may be necessary for confirmation.

The rising prevalence of inhaling airborne fungal spores due to disturbances in the soil caused by factors like dust storms and construction activities is primarily driving the coccidioidomycosis market. In addition to this, the escalating incidence of somatic mutations in the GNAQ gene, leading to overgrowth of the fungus in certain regions of the body, particularly the respiratory system, is a crucial factor fueling the market growth. Furthermore, the increasing utilization of effective antifungal medications, such as azoles, polyenes, echinocandins, etc., to manage the condition and prevent complications is creating a positive outlook for the market. Apart from this, the widespread adoption of preventive measures, including wearing masks and avoiding high-risk areas, has also contributed to the market's expansion. Additionally, the rising popularity of early diagnosis through serological tests and chest X-rays, enabling prompt treatment and reducing disease progression, is acting as another significant growth-inducing factor. Moreover, the emerging trend of adopting combination therapy, involving a few different types of antifungal agents in severe cases, is further augmenting the market growth. Additionally, the growing research and development efforts towards launching a therapeutic vaccine aimed at providing long-term immunity and prevention against the disease are expected to drive the coccidioidomycosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the coccidioidomycosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for coccidioidomycosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the coccidioidomycosis market in any manner.

Key Highlights:

• Every year, around 25,000 new clinically apparent cases of coccidioidomycosis are recorded in the United States.
• This illness is responsible for up to 75 deaths each year.
• According to skin test results, 80% or more of residents who have lived in endemic areas for five years or longer will have a positive coccidioidin skin test.
• Positive skin test findings are common in the southern United States, with rates ranging from 50-70% and increasing with age.
• The frequency of cases of coccidioidomycosis in endemic areas increases dramatically in late summer and early fall when the soil dries.
• Pregnant women, particularly during the third trimester and the early postpartum period, are at a higher risk of dissemination than the general population.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the coccidioidomycosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the coccidioidomycosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current coccidioidomycosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the coccidioidomycosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the coccidioidomycosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the coccidioidomycosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of coccidioidomycosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of coccidioidomycosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of coccidioidomycosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with coccidioidomycosis across the seven major markets?
• What is the size of the coccidioidomycosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of coccidioidomycosis?
• What will be the growth rate of patients across the seven major markets?
   

Coccidioidomycosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for coccidioidomycosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the coccidioidomycosis market?
• What are the key regulatory events related to the coccidioidomycosis market?
• What is the structure of clinical trial landscape by status related to the coccidioidomycosis market?
• What is the structure of clinical trial landscape by phase related to the coccidioidomycosis market?
• What is the structure of clinical trial landscape by route of administration related to the coccidioidomycosis market?